MedTrace Logo

Named Patient Program With Rotigotine Transdermal System

NCT01095484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 520

Last updated 2014-10-20

No results posted yet for this study

Summary

The named patient program will allow investigators to supply rotigotine transdermal system to patients who have a documented medical necessity to receive treatment with the drug.

Conditions

  • Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

Interventions

DRUG

Rotigotine patch

1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095484 on ClinicalTrials.gov